A trial looking at ofatumumab for diffuse large B cell lymphoma that has come back after treatment

This trial looked ofatumumab for diffuse large B cell lymphoma that had come back or continued to grow after treatment.

It recruited people who either could not have a stem cell transplant using their own blood cells (autologous transplant), or had already had a stem cell transplant.

Diffuse large B cell lymphoma (DLBCL) is a type of high grade non Hodgkin lymphoma (NHL). Doctors often treat DLBCL with a combination of chemotherapy and a drug called rituximab. This treatment is called R-CHOP. This is a successful treatment for many people. But if the lymphoma comes back and you can’t have a stem cell transplant, or you have already had one, your lymphoma can be more difficult to treat.

Ofatumumab (Arzerra) is a type of biological therapy called a monoclonal antibody. These can seek out cancer cells by looking for particular proteins which are found on the surface of particular cancer cells.

The aims of the trial were to find out

• How well ofatumumab works for patients whose DLBCL has come back after treament

• More about the side effects